Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience

INTRODUCTION: Immunotherapy with nivolumab (a monoclonal antibody that targets the programmed cell death protein 1, PD1) has become the standard treatment for patients with metastatic renal cell carcinoma (mRCC) after progression to single-agent tyrosine kinase inhibitors. However, the optimal durat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bimbatti, Davide, Dionese, Michele, Lai, Eleonora, Cavasin, Nicolò, Basso, Umberto, Mattana, Alvise, Pierantoni, Francesco, Zagonel, Vittorina, Maruzzo, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411856/
https://www.ncbi.nlm.nih.gov/pubmed/36033511
http://dx.doi.org/10.3389/fonc.2022.960751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411856/
https://www.ncbi.nlm.nih.gov/pubmed/36033511
http://dx.doi.org/10.3389/fonc.2022.960751

Ejemplares similares